India, Aug. 21 -- Werewolf Therapeutics (HOWL) and Ambros Therapeutics have entered into a definitive merger agreement to combine in an all-stock deal. The combined company will focus on advancing Ambros Therapeutics neridronate development program in Complex Regional Pain Syndrome Type 1. Upon completion, the combined company will operate as Ambros Therapeutics, and is expected to trade under the Nasdaq ticker symbol AMBX. The combined company will be led by current members of the Ambros leadership team.
In connection with the proposed merger, the companies secured commitments for an oversubscribed concurrent private placement of $150 million from a syndicate of healthcare-dedicated investors. The private placement is expected to close co...